A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron(University of Leeds), Michelle Casey(GlaxoSmithKline (United States)), Michael F. Press(University of Southern California), Deborah Lindquist(Texas Oncology), Tadeusz Pieńkowski(Centrum Onkologii), C. Gilles Romieu(CEA Valduc), Stephen Chan(Nottingham University Hospitals NHS Trust), Agnieszka Jagiełło-Gruszfeld(University of Computer Sciences and Economics in Olsztyn), Bella Kaufman(Sheba Medical Center), John Crown(Cancer Trials Ireland), Arlene Chan(Mount Medical Centre), Mario Campone(Centre Hospitalier René-Dubos), Patrice Viens(Institut Paoli-Calmettes), Neville Davidson(Broomfield Hospital), Vera Gorbounova(Russian Cancer Research Center NN Blokhin), Johannes Isaac Raats(Cape Town Science Centre), Dimosthenis Skarlos(Henry Dunant Hospital), B. Newstat(GlaxoSmithKline (United States)), Debasish Roychowdhury(GlaxoSmithKline (United States)), Paolo Paoletti(GlaxoSmithKline (United States)), Cristina Oliva(GlaxoSmithKline (United States)), Stephen C. Rubin(GlaxoSmithKline (United States)), Steven Stein(GlaxoSmithKline (United States)), Charles E. Geyer(Allegheny General Hospital)
Cited by 803
Abstract
Related Papers
No related papers found
Powered by citation graph analysis